^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Solid Tumor
    Drug:GDA-501 (NK cell stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2022
    Title:

    273 GDA-501: Engineered NAM-NK cells with HER2-CAR expression demonstrate increased cytotoxicity against HER2-expressing solid tumors

    Published date:
    11/08/2022
    Excerpt:
    In vitro data demonstrated potent cytotoxicity against HER2-expressing cells. These results suggest that GDA-501 represents a unique allogeneic cell therapy potentially targeting HER2+ solid tumors.
    DOI:
    http://dx.doi.org/10.1136/jitc-2022-SITC2022.0273